Actividad in vitro de moxifloxacino frente a patógenos respiratorios en iberoamérica

Translated title of the contribution: In vitro activity of moxifloxacin against respiratory pathogens in Latin America

H. López, H. Sader, C. Amábile, W. Pedreira, J. L. Muñoz Bellido, J. A. García Rodríguez, P. García, V. Prado, J. Robledo, O. Sussmann, Y. Blandon, P. Díaz, G. Ponce, F. Quiñones, R. Fagundo, D. Akle, G. Barriga, A. Guillén, R. Zerpa, J. L. BauerM. Comegna, B. Gallegos

    Research output: Contribution to journalArticlepeer-review

    4 Scopus citations

    Abstract

    We compared the in vitro activity of moxifloxacin, levofloxacin and six other antibiotics frequently used in respiratory tract infections, against 1563 Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis clinical isolates from 21 centers in 10 Latin American countries from March 2000 to April 2001. Moxifloxacin was the most active compound against all the species included. Moxifloxacin was 2- to 4-fold more active than levofloxacin against Gram-positive bacteria. This difference was much higher against levofloxacin-resistant S. pneumoniae isolates (MIC. 0.5 mg/l vs 8 mg/l). The activity of moxifloxacin against H. influenzae and M. catarrhalis was similar to levofloxacin; all the isolates were inhibited at ≤1 mg/l concentrations of moxifloxacin and levofloxacin.

    Translated title of the contributionIn vitro activity of moxifloxacin against respiratory pathogens in Latin America
    Original languageSpanish
    Pages (from-to)325-334
    Number of pages10
    JournalRevista Espanola de Quimioterapia
    Volume15
    Issue number4
    StatePublished - Dec 2002

    Fingerprint

    Dive into the research topics of 'In vitro activity of moxifloxacin against respiratory pathogens in Latin America'. Together they form a unique fingerprint.

    Cite this